HCC
REGN icon

Hirtle Callaghan & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Hirtle Callaghan & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
+390
New +$265K 0.01% 118
2015
Q1 		– Sell
-3
Closed -$1K – 288
2014
Q4 		$1K Buy
+3
New +$1.18K ﹤0.01% 545
2014
Q3 		– Sell
-3
Closed -$1K – 616
2014
Q2 		$1K Hold
3
– – ﹤0.01% 622
2014
Q1 		$1K Buy
3
+1
+50% +$308 ﹤0.01% 613
2013
Q4 		$1K Sell
2
-1
-33% -$288 ﹤0.01% 591
2013
Q3 		$1K Buy
+3
New +$789 ﹤0.01% 601

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hirtle Callaghan & Co's REGN Position: Q2 2026 in Review

Hirtle Callaghan & Co opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 390 shares worth $243K. The stake represents 0.01% of the portfolio and ranks #118 among its holdings. This is a return to the name: Hirtle Callaghan & Co previously reported a position in REGN as recently as Q4 2014.

Hirtle Callaghan & Co first reported a position in REGN in Q3 2013 and has held it in 6 quarters since. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hirtle Callaghan & Co held 390 shares of Regeneron Pharmaceuticals worth $243K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Hirtle Callaghan & Co position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Hirtle Callaghan & Co's portfolio in Q2 2026, its #118 holding.
  • Hirtle Callaghan & Co first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 6 quarters since.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hirtle Callaghan & Co's 13F filing for Q2 2026, filed 14 Aug 2026.